FDA's traditional approval of encorafenib followed earlier accelerated approval in same indicationNov 9Regulatory decisionencorafenibPfizerUpdated
Lilly-linked brain metastases trial posts results; two baricitinib studies completeOct 30Weekly roundup, 4 itemsabemaciclibadagrasibUpdated
Wave Life Sciences details Q3 2026 progress on WVE-006, WVE-007, WVE-008 pipelineOct 28Quarterly updateBristol Myers SquibbEli LillyUpdated
Avutometinib-defactinib trial in mesonephric gynecologic cancer stays active, not recruitingOct 8Trial updateavutometinibdefactinib
Incyte posts terminated Phase 1 KRASG12C combo results; registers new INCB161734 mass balance studySep 11Weekly roundup, 2 itemsadagrasibBristol Myers Squibb
BMS logs three FDA label approvals and posts results for melanoma combo trialSep 2Weekly roundup, 5 itemsadagrasibBristol Myers Squibb
Kura Oncology posts $9.1 million in KOMZIFTI revenue in second quarter of 2026Aug 12Quarterly updateKura Oncology, Inc.ziftomenib
Verastem registers open-label extension study for avutometinib-defactinib in LGSOCAug 5Trial updateavutometinibdefactinib
BMS week: two label updates, new luspatercept CKD trial, pulmonary fibrosis study registeredJul 24Weekly roundup, 6 itemsadagrasibBristol Myers Squibb